エメンド・バイオセラピューティクス、オムニ・ヌクレアーゼ・プログラムでタケダとの協力におけるマイルストーンを達成 ニューヨーク発 , Aug. 20, 2019 (GLOBE NEWSWIRE) -- エメンド・バイオセラピューティクス (Emendo Biotherapeutics) は本日、武田薬品工業株式会社 (Takeda Pharmaceutical Company Limited、タケダ)...

Emendo Biotherapeutics Achieves Milestone of Collaboration with Takeda for its OMNI Nuclease Program NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics today announced that the company achieved the first milestone as laid out in the agreements with Takeda Pharmaceutical Company...

Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Emendo Biotherapeutics Inc. today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of...